Nuwellis Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.6455
- Today's High:
- $1.7152
- Open Price:
- $1.65
- 52W Low:
- $1.51
- 52W High:
- $76
- Prev. Close:
- $1.68
- Volume:
- 44774
Company Statistics
- Market Cap.:
- $3.34 million
- Book Value:
- 5.94
- Revenue TTM:
- $8.31 million
- Operating Margin TTM:
- -232.71%
- Gross Profit TTM:
- $4.76 million
- Profit Margin:
- -205.85%
- Return on Assets TTM:
- -64.34%
- Return on Equity TTM:
- -118.98%
Company Profile
Nuwellis Inc had its IPO on 2012-02-16 under the ticker symbol NUWE.
The company operates in the Healthcare sector and Medical Devices industry. Nuwellis Inc has a staff strength of 70 employees.
Stock update
Shares of Nuwellis Inc opened at $1.65 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.65 - $1.72, and closed at $1.65.
This is a -1.79% slip from the previous day's closing price.
A total volume of 44,774 shares were traded at the close of the day’s session.
In the last one week, shares of Nuwellis Inc have slipped by -7.82%.
Nuwellis Inc's Key Ratios
Nuwellis Inc has a market cap of $3.34 million, indicating a price to book ratio of 0.27 and a price to sales ratio of 0.3223.
In the last 12-months Nuwellis Inc’s revenue was $8.31 million with a gross profit of $4.76 million and an EBITDA of $-18992000. The EBITDA ratio measures Nuwellis Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Nuwellis Inc’s operating margin was -232.71% while its return on assets stood at -64.34% with a return of equity of -118.98%.
In Q2, Nuwellis Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 6.2%.
Nuwellis Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-10.17 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Nuwellis Inc’s profitability.
Nuwellis Inc stock is trading at a EV to sales ratio of 0.7284 and a EV to EBITDA ratio of 0.4367. Its price to sales ratio in the trailing 12-months stood at 0.3223.
Nuwellis Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $15.55 million
- Total Liabilities
- $3.83 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $65000
- Dividend Payout Ratio
- 0%
Nuwellis Inc ended 2024 with $15.55 million in total assets and $0 in total liabilities. Its intangible assets were valued at $15.55 million while shareholder equity stood at $11.07 million.
Nuwellis Inc ended 2024 with $0 in deferred long-term liabilities, $3.83 million in other current liabilities, in common stock, $-278747000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $8.90 million and cash and short-term investments were $8.90 million. The company’s total short-term debt was $220,000 while long-term debt stood at $0.
Nuwellis Inc’s total current assets stands at $13.75 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $1.18 million compared to accounts payable of $2.31 million and inventory worth $2.73 million.
In 2024, Nuwellis Inc's operating cash flow was $0 while its capital expenditure stood at $65000.
Comparatively, Nuwellis Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.65
- 52-Week High
- $76
- 52-Week Low
- $1.51
- Analyst Target Price
- $9.4
Nuwellis Inc stock is currently trading at $1.65 per share. It touched a 52-week high of $76 and a 52-week low of $76. Analysts tracking the stock have a 12-month average target price of $9.4.
Its 50-day moving average was $2.12 and 200-day moving average was $5.33 The short ratio stood at 0.19 indicating a short percent outstanding of 0%.
Around 47.2% of the company’s stock are held by insiders while 100.3% are held by institutions.
Frequently Asked Questions About Nuwellis Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company’s products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama. Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.